Back to top

Analyst Blog

Zacks Equity Research

Sanofi to Slash Workforce in France

SNY

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Sanofi (SNY - Analyst Report) recently announced that it plans to reduce its workforce in France by approximately 900 positions by 2015. Sanofi intends to put this plan into action through early retirement plans, mobility proposals and repositioning in France. Sanofi discussed this plan as a part of a restructuring project in France.

Sanofi has undertaken this project with the objective of increasing the success of research activities, improving the performance of the vaccines division, Sanofi Pasteur, and optimize efficiency by streamlining support functions.

We remind investors that earlier this year, Sanofi saw two of its key products losing patent protection. With both Avapro and Plavix facing generic competition, Sanofi’s business net income is expected to be negatively impacted by around €1.4 billion in 2012. Additionally, several other products of the company including Lovenox, Xatral and Taxotere are already facing generic erosion.

In order to address its generic concerns, Sanofi reviewed its cost base and implemented a new operating model. The company conducted an extensive review of its research and development operations in order to reallocate resources to the highest growth and most promising development programs. The new operating model should result in significant cost cutting in R&D and SG&A.

Sanofi delivered cost savings of €2 billion by the end of 2011. The company remains on track to generate additional cost savings of €2 billion by 2015. The company expects to realize one-third of this saving by the beginning of 2013. The company has also been working on allocating resources to the highest growth and most promising development programs.

Our Recommendation

We currently have a Neutral recommendation on Sanofi. The stock carries a Zacks #3 Rank (Hold rating) in the short run. We are pleased with the company’s efforts to develop its pipeline. We expect Sanofi to continue to contain operating costs in order to increase earnings in the face of weakening sales of some of its biggest products. We also expect the company to pursue bolt-on acquisitions.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%